Approval · Notice of Compliance 20337 · 2018
IPRAVENT: Notice of Compliance 20337
Issued January 16, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20337
- Date
- January 16, 2018
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Updates to the product monograph
- Canadian reference product
- ATROVENT NASAL SPRAY (Boehringer Ingelheim (Canada) Ltd.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IPRAVENT | Not yet assigned | — |
Medicinal ingredients
- IPRATROPIUM BROMIDE 0.03 PER
- IPRATROPIUM BROMIDE 0.06 PER